.

0 (hodnocen0 x )

EB

ONLINE

Washington, District of Columbia : National Academies Press, [2013]

1 online resource (170 pages) : illustrations (some color)

ISBN 9780309265966 (electronic bk.)

ISBN 0309265959

ISBN 9780309265959

Print version: Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis : workshop summary. Washington, District of Columbia : National Academies Press, [2013] xvii, 152 pages ; 24 cm ISBN 9780309265959

"Forum on drug discovery, development, and translation."--Cover

"Workshop was held on July 31- August 1, 2012 in Washington, D.C

Includes bibliographical references (pages 111-113)

Logistics, Supply, and Demand -- Financing of MDR TB SLDs -- Innovative Suggestions and Potential Solutions.

Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review: To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks ; The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain ; What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S.-.

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB) a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin) face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities.-.

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB) a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin) face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities.-.

001826340

full

(Au-PeEL)EBL3379261

(CaPaEBR)ebr10863916

(MiAaPQ)EBC3379261

(OCoLC)823904672